Technology Available for Industry-Academia Collaboration or Technology Licensing. “Opioid Receptor Allosteric Modifier: DBPR116” (2021/1/28)

Title:NHRI technology, “Opioid Receptor Allosteric Modifier: DBPR116” (abbreviated as “The Technology”) available for industry-academia collaboration or technology licensing. Description:The Technology relates to antagonist-to-agonist allosteric modifiers (AAM) of a mu-opioid receptor (MOR) for treating an opioid receptor-associated condition. In the presence of this unique AAM (DBPR116), MOR could be selective activated…

Continue reading

NHRI technology, “Induction of Stem Cell-derived Exosomes for Disease Treatment” available for technology licensing (exclusive license), 2020/08/17

Subject NHRI technology, “Induction of Stem Cell-derived Exosomes for Disease Treatment” (abbreviated as “The Technology”) available for technology licensing (exclusive license). Description The Technology is to use induced stem cell-derived exosomes, instead of stem cells, as regeneration medicine. The invention is a method of inducing stem cells to release exosomes…

Continue reading

Technology Available for Technology Licensing. “Method and composition for decreasing the psychotomimetic side effect and addictive disorder of ketamine(Jul 20,2020)

1.Title “Method and composition for decreasing the psychotomimetic side effect and addictive disorder of ketamine” (abbreviated as “The Technology”) available for technology licensing. 2.Description: The present invention relates to a method for reducing the addictive andpsychotomimetic side effects of ketamine and enhancing the medical efficacy of ketamine. It is characterized…

Continue reading

Building a Biomedical Value Chain and Accelerating the Development of the Biomedical Industry

台灣有超過上百家育成中心,主要提供新創公司和中小企業在發展前期的資源,其中包含了空間、儀器設備、研發技術、資金連結、商務服務、管理諮詢等,以降低其創業初期的成本與風險。多數育成中心設置在大學與政府機構。其中,國家衛生研究院技轉及育成中心專注於生物科技與醫療衛生領域 ,多年以來更是扮演台灣生醫產業發展的重要推手。

Continue reading

Technology Available for Industry-Academia Collaboration or Technology Licensing. “A Potential COVID-19 Therapeutic Compound”(2020/4/16)

技術移轉

1. Title: NHRI technology, “A Potential COVID-19 Therapeutic Compound” (abbreviated as “The Technology”) available for industry-academia collaboration or technology licensing. 2. Description: The Technology is a novel compound which, in coronaviral infected cells, targets the RNP complex containing viral RNA and nucleoprotein to block viral replication and activities for anti-coronaviral mechanism….

Continue reading